Workshop Feedback

China: Key issues at stake for developing the efficient provision of healthcare product?

Co-leaders:
Prof. Ye Lu, Director of the Department of Health Economics, Fudan School of Public Health, China

Mr. Amish Chaturvedi, Market Access Director, AbbVie Japan Asia-Pacific, Singapore
Question 1: Potential for Government-Industry partnership to improve access and affordability

• Challenges
  – More transparency in decision making
  – Dialogue between industry and Government
  – Lack of consistency in advice
  – Lack of communication channels
  – Diversity and geography
  – Expectations

• Opportunities
  – Industry to provide good examples of partnerships in other countries
  – Replicate the success of local level engagements more broadly
  – Industry partnerships e.g. with Private Health Insurance to improve affordability
Question 2: Technology transfer and partnerships to improve R&D capacity in China

• Key barriers
  – “No Choice” situation
  – Lack of appreciation of long term benefits of tech transfer to the wider economy
  – Lack of trust – Opportunities often regarded as ‘high risk’
  – Uncertainty of ‘return on investments’

• Potential solutions
  – No easy solutions ....
Question 3: HTA in China

• **What will it look like or what should it look like?**
  – HTA is important for China and establishing relative value is seen crucial. However, local companies limited experience to conduct HTA

• **Government needs to strike a balance**
  – Capacity building in HTA needed
    -> Role of government to incentivize
  – Need for a National HTA body
  – Access to claims data